GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BeyondSpring Inc (NAS:BYSI) » Definitions » Loans Receivable

BeyondSpring (BeyondSpring) Loans Receivable : $0.00 Mil (As of Dec. 2023)


View and export this data going back to 2017. Start your Free Trial

What is BeyondSpring Loans Receivable?

BeyondSpring's Loans Receivable for the quarter that ended in Dec. 2023 was $0.00 Mil.


BeyondSpring Loans Receivable Historical Data

The historical data trend for BeyondSpring's Loans Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BeyondSpring Loans Receivable Chart

BeyondSpring Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Loans Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

BeyondSpring Quarterly Data
Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Jun22 Dec22 Jun23 Dec23
Loans Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

BeyondSpring Loans Receivable Calculation

Loans Receivable are the funds that a company has lent but have not yet been repaid.


BeyondSpring Loans Receivable Related Terms

Thank you for viewing the detailed overview of BeyondSpring's Loans Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


BeyondSpring (BeyondSpring) Business Description

Traded in Other Exchanges
N/A
Address
28 Liberty Street, 39th Floor, New York, NY, USA, 10005
BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It has two reportable segments Plinabulin pipeline and the TPD platform. It has a scalable business model integrating clinical resources in the United States and China.